Pharma Focus America

Belharra Therapeutics Forms Alliance with Sanofi to Develop Novel Treatments for Immune System Disorders

Wednesday, June 19, 2024

Belharra Therapeutics, a company specializing in chemoproteomics for small molecule drug discovery, has announced a strategic collaboration with Sanofi aimed at developing new small molecule therapies for immunological diseases. The partnership will utilize Belharra’s proprietary non-covalent chemoproteomics platform to screen and validate potential drug candidates against undisclosed immunology targets selected by Sanofi.

Under the terms of the agreement, Belharra stands to receive up to $40 million in upfront and near-term milestone payments, with a total potential deal value nearing $700 million, inclusive of payments tied to research, development, and commercial milestones, as well as tiered royalties on net sales.

Belharra, expressed enthusiasm about the collaboration, stating, “We are eager to combine Belharra’s advanced chemoproteomics platform with Sanofi’s extensive expertise in immunology research and development. Our platform allows for comprehensive and unbiased screening of potential drug interactions, offering insights that can lead to the discovery of new therapeutic options in oncology and immunology.”

John Bertin, Global Head of Immunology and Inflammation Research at Sanofi emphasized the strategic importance of the collaboration, saying, “Partnering with Belharra underscores our commitment to advancing treatments for chronic inflammatory diseases. By leveraging Belharra’s platform, we aim to explore new therapeutic targets in immunology that were previously considered challenging.”

Belharra’s chemoproteomics platform utilizes a library of non-covalent molecules designed for photoaffinity chemistry to identify protein binding sites within a cellular environment. This approach enables the identification of binding pockets on various proteins, facilitating the discovery of potential new drugs and therapeutic targets.



Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024